<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Allergy &amp; Clinical Immunology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/allergy-immunology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Azelastine-fluticasone combo effective for seasonal allergic rhinitis</title>
		<link>http://www.thedoctorschannel.com/view/azelastine-fluticasone-combo-effective-for-seasonal-allergic-rhinitis/</link>
		<pubDate>Mon, 02 Apr 2012 22:37:09 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[allergic rhinitis]]></category>
		<category><![CDATA[azelastine]]></category>
		<category><![CDATA[Dymista]]></category>
		<category><![CDATA[fluticasone]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27576</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – An investigational formulation of azelastine and fluticasone (MP29-02) is more effective than either agent alone as intranasal therapy for moderate-to-severe seasonal allergic rhinitis (SAR), according to the pooled results of three randomized, controlled trials. “This provides sound clinical evidence, for the first time, that intranasal antihistamines and corticosteroids have complementary -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[Azelastine-fluticasone combo effective for seasonal allergic rhinitis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – An investigational formulation of azelastine and fluticasone (MP29-02) is more effective than either agent alone as intranasal therapy for moderate-to-severe seasonal allergic rhinitis (SAR), according to the pooled results of three randomized, controlled trials. “This provides sound clinical evidence, for the first time, that intranasal antihistamines and corticosteroids have complementary -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/azelastine-fluticasone-combo-effective-for-seasonal-allergic-rhinitis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120402drgd001.jpg"/>
	<media:keywords><![CDATA[allergic rhinitis,azelastine,Dymista,fluticasone]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Muscle relaxants, most neuromodulators don&#8217;t help RA pain</title>
		<link>http://www.thedoctorschannel.com/view/muscle-relaxants-most-neuromodulators-dont-help-ra-pain/</link>
		<pubDate>Thu, 26 Jan 2012 19:26:53 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pain Management]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[benzodiazepine]]></category>
		<category><![CDATA[cannabis]]></category>
		<category><![CDATA[capsaicin]]></category>
		<category><![CDATA[muscle relaxants]]></category>
		<category><![CDATA[neuromodulators]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<category><![CDATA[zopiclone]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=24067</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Muscle relaxants don&#8217;t ease the pain of rheumatoid arthritis (RA), and only topical capsaicin among studied neuromodulators offers some relief, according to two reviews published January 18 in the Cochrane Library. &#8220;Pain management is a high priority&#8221; for RA patients, but &#8220;there is currently a paucity of data&#8221; to guide -]]></description>
		
			<media:content duration="1:38" medium="video">
		<media:title><![CDATA[Muscle relaxants, most neuromodulators don&#8217;t help RA pain]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Muscle relaxants don&#8217;t ease the pain of rheumatoid arthritis (RA), and only topical capsaicin among studied neuromodulators offers some relief, according to two reviews published January 18 in the Cochrane Library. &#8220;Pain management is a high priority&#8221; for RA patients, but &#8220;there is currently a paucity of data&#8221; to guide -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/muscle-relaxants-most-neuromodulators-dont-help-ra-pain/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/01/Screen-shot-2012-01-26-at-2.25.26-PM.png"/>
	<media:keywords><![CDATA[benzodiazepine,cannabis,capsaicin,muscle relaxants,neuromodulators,RA,rheumatoid arthritis,zopiclone]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Sublingual and oral immunotherapy shows promise for milk allergy</title>
		<link>http://www.thedoctorschannel.com/view/sublingual-and-oral-immunotherapy-shows-promise-for-milk-allergy/</link>
		<pubDate>Thu, 05 Jan 2012 21:50:10 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[cow's milk allergy]]></category>
		<category><![CDATA[desensitize]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22762</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Sublingual and oral immunotherapy may help some children with milk allergy, but clinical desensitization is quickly lost and systemic reactions occur with oral therapy, a new study shows. “We found that both sublingual and oral immunotherapy benefited children with cow&#8217;s milk allergy in that they were able to consume much -]]></description>
		
			<media:content duration="1:48" medium="video">
		<media:title><![CDATA[Sublingual and oral immunotherapy shows promise for milk allergy]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Sublingual and oral immunotherapy may help some children with milk allergy, but clinical desensitization is quickly lost and systemic reactions occur with oral therapy, a new study shows. “We found that both sublingual and oral immunotherapy benefited children with cow&#8217;s milk allergy in that they were able to consume much -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/sublingual-and-oral-immunotherapy-shows-promise-for-milk-allergy/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/01/Screen-shot-2012-01-05-at-4.52.07-PM.png"/>
	<media:keywords><![CDATA[cow's milk allergy,desensitize,immunotherapy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>H3 receptor antagonist may help relieve allergic rhinitis symptoms</title>
		<link>http://www.thedoctorschannel.com/view/h3-receptor-antagonist-may-help-relieve-allergic-rhinitis-symptoms/</link>
		<pubDate>Thu, 05 Jan 2012 00:22:04 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[allergic rhinitis]]></category>
		<category><![CDATA[fexofenadine]]></category>
		<category><![CDATA[H3 receptor antagonist]]></category>
		<category><![CDATA[pseudoephedrine]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22737</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The effects of an H1 receptor antagonist in reducing allergen-induced nasal symptoms appear to be enhanced with the addition of an H3 receptor antagonist, according to the results of a challenge study reported online December 26 in the Journal of Allergy and Clinical Immunology. As a summary of the clinical -]]></description>
		
			<media:content duration="1:38" medium="video">
		<media:title><![CDATA[H3 receptor antagonist may help relieve allergic rhinitis symptoms]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The effects of an H1 receptor antagonist in reducing allergen-induced nasal symptoms appear to be enhanced with the addition of an H3 receptor antagonist, according to the results of a challenge study reported online December 26 in the Journal of Allergy and Clinical Immunology. As a summary of the clinical -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/h3-receptor-antagonist-may-help-relieve-allergic-rhinitis-symptoms/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/01/Screen-shot-2012-01-04-at-6.16.16-PM.png"/>
	<media:keywords><![CDATA[allergic rhinitis,fexofenadine,H3 receptor antagonist,pseudoephedrine]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>TNF inhibitors overall not linked to serious infections</title>
		<link>http://www.thedoctorschannel.com/view/tnf-inhibitors-overall-not-linked-to-serious-infections/</link>
		<pubDate>Sat, 12 Nov 2011 07:11:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[autoimmune diseases]]></category>
		<category><![CDATA[TNF]]></category>
		<category><![CDATA[tumor necrosis factor]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/tnf-inhibitors-overall-not-linked-to-serious-infections/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Contrary to persistent concerns, the use of tumor necrosis factor (TNF)-alpha antagonists, as a group, to treat autoimmune diseases is not associated with an increased risk of hospitalization for infection in the year after starting treatment, according to a report in the Journal of the American Medical Association online November -]]></description>
		
			<media:content duration="1:38" medium="video">
		<media:title><![CDATA[TNF inhibitors overall not linked to serious infections]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Contrary to persistent concerns, the use of tumor necrosis factor (TNF)-alpha antagonists, as a group, to treat autoimmune diseases is not associated with an increased risk of hospitalization for infection in the year after starting treatment, according to a report in the Journal of the American Medical Association online November -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/tnf-inhibitors-overall-not-linked-to-serious-infections/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4819.jpg"/>
	<media:keywords><![CDATA[autoimmune diseases,TNF,tumor necrosis factor]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>New report focuses on managing food allergy in children</title>
		<link>http://www.thedoctorschannel.com/view/new-report-focuses-on-managing-food-allergy-in-children/</link>
		<pubDate>Fri, 14 Oct 2011 18:48:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[allergies]]></category>
		<category><![CDATA[food allergies]]></category>
		<category><![CDATA[food allergy]]></category>
		<category><![CDATA[Pediatric Allergy and Immunology]]></category>
		<category><![CDATA[pediatrics]]></category>
		<category><![CDATA[Wesley Burks]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/new-report-focuses-on-managing-food-allergy-in-children/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Managing food allergy in infants, children and adolescents is nothing short of challenging, for a whole host of reasons. A State-of-the-Art Review Article in the November issue of Pediatrics summarizes current U.S. guidelines for the diagnosis and management of food allergy that are most pertinent to the pediatric population. &#8220;Food -]]></description>
		
			<media:content duration="2:06" medium="video">
		<media:title><![CDATA[New report focuses on managing food allergy in children]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Managing food allergy in infants, children and adolescents is nothing short of challenging, for a whole host of reasons. A State-of-the-Art Review Article in the November issue of Pediatrics summarizes current U.S. guidelines for the diagnosis and management of food allergy that are most pertinent to the pediatric population. &#8220;Food -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/new-report-focuses-on-managing-food-allergy-in-children/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4762.jpg"/>
	<media:keywords><![CDATA[allergies,food allergies,food allergy,Pediatric Allergy and Immunology,pediatrics,Wesley Burks]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Efficacy of sublingual immunotherapy for grass pollen allergy sustained over time</title>
		<link>http://www.thedoctorschannel.com/view/efficacy-of-sublingual-immunotherapy-for-grass-pollen-allergy-sustained-over-time/</link>
		<pubDate>Wed, 10 Aug 2011 20:38:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dr. Alain Didier]]></category>
		<category><![CDATA[grass pollen allergy]]></category>
		<category><![CDATA[Journal of Allergy and Clinical Immunology]]></category>
		<category><![CDATA[SLIT]]></category>
		<category><![CDATA[sublingual immunotherapy]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/efficacy-of-sublingual-immunotherapy-for-grass-pollen-allergy-sustained-over-time/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A regimen of pre-seasonal and seasonal sublingual immunotherapy (SLIT) for grass pollen allergy reduces symptoms by more than a third after three pollen seasons, a multicenter team reports in the Journal of Allergy and Clinical Immunology online August 1. The treatment is well tolerated, the authors report, and in fact, -]]></description>
		
			<media:content duration="1:35" medium="video">
		<media:title><![CDATA[Efficacy of sublingual immunotherapy for grass pollen allergy sustained over time]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A regimen of pre-seasonal and seasonal sublingual immunotherapy (SLIT) for grass pollen allergy reduces symptoms by more than a third after three pollen seasons, a multicenter team reports in the Journal of Allergy and Clinical Immunology online August 1. The treatment is well tolerated, the authors report, and in fact, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/efficacy-of-sublingual-immunotherapy-for-grass-pollen-allergy-sustained-over-time/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4602.jpg"/>
	<media:keywords><![CDATA[Dr. Alain Didier,grass pollen allergy,Journal of Allergy and Clinical Immunology,SLIT,sublingual immunotherapy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Full flu vaccine dose safe, more immunogenic in infants</title>
		<link>http://www.thedoctorschannel.com/view/full-flu-vaccine-dose-safe-more-immunogenic-in-infants/</link>
		<pubDate>Tue, 19 Jul 2011 21:39:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Neonatology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Resource Center: Pediatric Vaccinations]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dr. Danuta M. Skowronski]]></category>
		<category><![CDATA[Flu Vaccine]]></category>
		<category><![CDATA[infants]]></category>
		<category><![CDATA[pediatrics]]></category>
		<category><![CDATA[preemies]]></category>
		<category><![CDATA[split-virus trivalent influenza vaccine]]></category>
		<category><![CDATA[TIV]]></category>
		<category><![CDATA[toddlers]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/full-flu-vaccine-dose-safe-more-immunogenic-in-infants/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Infants and toddlers aged 6 to 23 months in North America are currently given a half-dose of split-virus trivalent influenza vaccine (TIV), but a full dose is more immunogenic and does not increase the risk of fever, according to the results of a randomized controlled trial conducted in Canada. “Current -]]></description>
		
			<media:content duration="1:20" medium="video">
		<media:title><![CDATA[Full flu vaccine dose safe, more immunogenic in infants]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Infants and toddlers aged 6 to 23 months in North America are currently given a half-dose of split-virus trivalent influenza vaccine (TIV), but a full dose is more immunogenic and does not increase the risk of fever, according to the results of a randomized controlled trial conducted in Canada. “Current -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/full-flu-vaccine-dose-safe-more-immunogenic-in-infants/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4550.jpg"/>
	<media:keywords><![CDATA[Dr. Danuta M. Skowronski,Flu Vaccine,infants,pediatrics,preemies,split-virus trivalent influenza vaccine,TIV,toddlers]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>DMARDs may decrease diabetes risk in RA and psoriasis</title>
		<link>http://www.thedoctorschannel.com/view/dmards-may-decrease-diabetes-risk-in-ra-and-psoriasis/</link>
		<pubDate>Fri, 24 Jun 2011 21:12:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[disease-modifying antirheumatic drugs]]></category>
		<category><![CDATA[DMARDs]]></category>
		<category><![CDATA[Dr. Daniel Solomon]]></category>
		<category><![CDATA[Journal of the American Medical Association]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<category><![CDATA[TNF]]></category>
		<category><![CDATA[tumor necrosis factor]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/dmards-may-decrease-diabetes-risk-in-ra-and-psoriasis/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Certain disease-modifying antirheumatic drugs (DMARDs) may lower the risk of diabetes in patients with rheumatoid arthritis (RA) or psoriasis, according to an observational study just published. Among nearly 14,000 patients with RA or psoriasis, researchers found that the use of a tumor necrosis factor (TNF) inhibitor or hydroxychloroquine was associated -]]></description>
		
			<media:content duration="1:48" medium="video">
		<media:title><![CDATA[DMARDs may decrease diabetes risk in RA and psoriasis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Certain disease-modifying antirheumatic drugs (DMARDs) may lower the risk of diabetes in patients with rheumatoid arthritis (RA) or psoriasis, according to an observational study just published. Among nearly 14,000 patients with RA or psoriasis, researchers found that the use of a tumor necrosis factor (TNF) inhibitor or hydroxychloroquine was associated -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/dmards-may-decrease-diabetes-risk-in-ra-and-psoriasis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4474.jpg"/>
	<media:keywords><![CDATA[diabetes,disease-modifying antirheumatic drugs,DMARDs,Dr. Daniel Solomon,Journal of the American Medical Association,psoriasis,RA,rheumatoid arthritis,TNF,tumor necrosis factor]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adding tiotropium improves lung function in severe asthma</title>
		<link>http://www.thedoctorschannel.com/view/adding-tiotropium-improves-lung-function-in-severe-asthma/</link>
		<pubDate>Wed, 15 Jun 2011 16:33:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dr. Huib A. M. Kerstjens]]></category>
		<category><![CDATA[Journal of Allergy and Clinical Immunology]]></category>
		<category><![CDATA[Lung Function]]></category>
		<category><![CDATA[severe uncontrolled asthma]]></category>
		<category><![CDATA[Tiotropium]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/adding-tiotropium-improves-lung-function-in-severe-asthma/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For patients with severe uncontrolled asthma, adding inhaled tiotropium to standard treatment improves lung function significantly, according to a study published June 3rd online by the Journal of Allergy and Clinical Immunology. The authors note that patients with severe asthma may remain obstructed after up-titration of an inhaled corticosteroid and -]]></description>
		
			<media:content duration="1:30" medium="video">
		<media:title><![CDATA[Adding tiotropium improves lung function in severe asthma]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For patients with severe uncontrolled asthma, adding inhaled tiotropium to standard treatment improves lung function significantly, according to a study published June 3rd online by the Journal of Allergy and Clinical Immunology. The authors note that patients with severe asthma may remain obstructed after up-titration of an inhaled corticosteroid and -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adding-tiotropium-improves-lung-function-in-severe-asthma/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4446.jpg"/>
	<media:keywords><![CDATA[Dr. Huib A. M. Kerstjens,Journal of Allergy and Clinical Immunology,Lung Function,severe uncontrolled asthma,Tiotropium]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
